To assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) and an inadequate response to antidepressant therapy
Qualified Participants Must:
Be 18 years of age or older
Be diagnosed with Major Depressive Disorder
Qualified Participants May Receive:
If enrolled, qualified participants will receive compensation for participation, time, and travel.